The functions and structure of ABC transporters: implications for the design of new inhibitors of Pgp and MRP1 to control multidrug resistance (MDR).

Abstract:

:Multidrug resistance (MDR) is a kind of acquired resistance of microorganisms and cancer cells to chemotherapic drugs that are characterized by different chemical structure and different mechanism of action. Classic MDR is the consequence of the over-expression of a variety of proteins that extrude the chemotherapic from the cell, lowering its concentration below the effective one. The ABC (ATP Binding Cassette) is a ubiquitous and important family of such transporter proteins. Members of this super family are present in mammals as well as in prokaryotic organisms and use ATP as the energy source to activate the extrusion process. P-glycoprotein (Pgp) and Multidrug Resistance Proteins (MRP1 and sister proteins) are the most important and widely studied members of ABC super family. Our knowledge about the structures and functions of transporter proteins has definitely improved in recent years, following the resolution of the structure of bacterial pumps which opened the way to the building of homology models for the more complex Pgp and MRP. It can be anticipated that these results will have a strong impact on the design of more potent and safer MDR reverters. A huge number of small molecules, many of natural origin, are able to reverse multidrug resistance by inhibiting the functions of Pgp, MRP1 and sister proteins and their action has been considered a possible way to reverse MDR. However, while a few compounds have reached clinical trials, none of them has, so far, been cleared for therapeutic use. Two main reasons are at the base of this difficulty: i) MDR is a complex phenomenon that may arise from several different biochemical mechanisms, with the consequence that inhibition of transporter proteins may be insufficient to reverse it; ii) the physiological role of Pgp and sister proteins requires more potent modulators with proper selectivity and pharmacokinetic in order to avoid unwanted side effects. This paper first reviews the most recent discoveries on the structures and functions of the ABC super family, in particular Pgp and MRP. Then, the medicinal chemistry of MDR reverters, in light of these findings, is discussed and the molecules that are presently in development are reviewed.

journal_name

Curr Drug Targets

journal_title

Current drug targets

authors

Teodori E,Dei S,Martelli C,Scapecchi S,Gualtieri F

doi

10.2174/138945006777709520

subject

Has Abstract

pub_date

2006-07-01 00:00:00

pages

893-909

issue

7

eissn

1389-4501

issn

1873-5592

journal_volume

7

pub_type

杂志文章,评审
  • The Therapeutic Potential of Quercetin in Parkinson's Disease: Insights into its Molecular and Cellular Regulation.

    abstract::Parkinson's disease (PD) is a chronic and progressive neurodegenerative disorder characterized by the progressive death of dopaminergic neurons in the substantia nigra pars compacta (SNc). PD is a multifactorial disorder, with several different factors being suggested to play a synergistic pathophysiological role, inc...

    journal_title:Current drug targets

    pub_type: 杂志文章

    doi:10.2174/1389450120666191112155654

    authors: Tamtaji OR,Hadinezhad T,Fallah M,Shahmirzadi AR,Taghizadeh M,Behnam M,Asemi Z

    更新日期:2020-01-01 00:00:00

  • Rationale and Prospects of Targeting Bacterial Two-component Systems for Antibacterial Treatment of Cystic Fibrosis Patients.

    abstract::Bacterial respiratory infections are the main reason of morbidity and mortality among cystic fibrosis (CF) patients. In early childhood, the respiratory infections are due to Staphylococcus aureus and Haemophilus influenzae. In older CF patients, pathogenic Gram-negative bacteria like Achromobacter xylosoxidans, Burkh...

    journal_title:Current drug targets

    pub_type: 杂志文章,评审

    doi:10.2174/1389450117666160208145934

    authors: Velikova N,Wells JM

    更新日期:2017-01-01 00:00:00

  • Non-steroidal anti-inflammatory drugs and cyclooxygenase in Alzheimer's disease.

    abstract::Epidemiological studies indicate that anti-inflammatory drugs, especially the non-steroidal anti-inflammatory drugs (NSAIDs), decrease the risk of developing Alzheimer's disease (AD). Their beneficial effects may be due to interference in the chronic inflammatory reaction, that takes place in AD. The best-characterize...

    journal_title:Current drug targets

    pub_type: 杂志文章,评审

    doi:10.2174/1389450033490902

    authors: Hoozemans JJ,Veerhuis R,Rozemuller AJ,Eikelenboom P

    更新日期:2003-08-01 00:00:00

  • Anti-tumor Drug Targets Analysis: Current Insight and Future Prospect.

    abstract::The incidence and mortality of malignant tumors are on the rise, which has become the second leading cause of death in the world. At present, anti-tumor drugs are one of the most common methods for treating cancer. In recent years, with the in-depth study of tumor biology and related disciplines, it has been gradually...

    journal_title:Current drug targets

    pub_type: 杂志文章,评审

    doi:10.2174/1389450120666190402145325

    authors: Wang S,Zhou D,Xu Z,Song J,Qian X,Lv X,Luan J

    更新日期:2019-01-01 00:00:00

  • Aldose reductase, still a compelling target for diabetic neuropathy.

    abstract::Aldose reductase (AR) enzymatically transforms cytosolic glucose into sorbitol, a molecule that poorly penetrates cell membranes and is sometimes slowly metabolized. Hyperglycemia can cause intracellular accumulation of sorbitol and its metabolite, fructose, which can create osmotic swelling and cell dysfunction. Driv...

    journal_title:Current drug targets

    pub_type: 杂志文章,评审

    doi:10.2174/138945008783431781

    authors: Oates PJ

    更新日期:2008-01-01 00:00:00

  • Nanotheranostics in evidence based personalized medicine.

    abstract::Efficient drug delivery systems are exceedingly important for novel drug discovery. The evidence-based personalized medicine (EBPM) promises to deliver the right drug at the right time to a right patient as it covers clinicallysignificant genetic predisposition and chronopharmacological aspects of nanotheranostics. Re...

    journal_title:Current drug targets

    pub_type: 杂志文章,评审

    doi:

    authors: Sharma S

    更新日期:2014-01-01 00:00:00

  • A new "era" for the α7-nAChR.

    abstract::The α7-nAChR plays critical roles in numerous organs and cells by regulating highly organ and cell typespecific functions. In this special issue different Authors have contributed to clarify the different roles played by the α7- nAChR. Post-translational processes such as receptor "underactivation" or "overactivation"...

    journal_title:Current drug targets

    pub_type: 杂志文章

    doi:10.2174/138945012800398946

    authors: Russo P,Cardinale A,Shuller H

    更新日期:2012-05-01 00:00:00

  • The Role of Type 2 Fibroblast Growth Factor in Periodontal Therapy.

    abstract::The prevalence of periodontitis is around 20-50% of global population. If not treated, it can cause of tooth loss. Periodontal treatment aims at preserving the patient's teeth from various methods, including infection control and restoring lost periodontal tissue. The periodontium has great biological regenerative pot...

    journal_title:Current drug targets

    pub_type: 杂志文章

    doi:10.2174/1389450121999201105152639

    authors: Mohammadipour HS,Forouzanfar F,Forouzanfar A

    更新日期:2020-11-05 00:00:00

  • Discovery and design of selective cyclooxygenase-2 inhibitors as non-ulcerogenic, anti-inflammatory drugs with potential utility as anti-cancer agents.

    abstract::The recent marketing of two selective cyclooxygenase-2 (COX-2) inhibitors, celecoxib and rofecoxib is remarkable considering that COX-2 was only discovered eight years ago as a growth factor- and cytokine-inducible gene. Concomitant with these pharmaceutical successes is the advances in our understanding of the molecu...

    journal_title:Current drug targets

    pub_type: 杂志文章,评审

    doi:10.2174/1389450013348830

    authors: Kalgutkar AS,Zhao Z

    更新日期:2001-03-01 00:00:00

  • Diacylglycerol kinases as emerging potential drug targets for a variety of diseases.

    abstract::Diacylglycerol (DAG) kinase (DGK) modulates the balance between the two signaling lipids, DAG and phosphatidic acid (PA), by phosphorylating (consuming) DAG to yield PA. Ten mammalian DGK isozymes have been identified to date. In addition to two or three cysteine-rich C1 domains (protein kinase C-like zinc finger stru...

    journal_title:Current drug targets

    pub_type: 杂志文章,评审

    doi:10.2174/138945008785132394

    authors: Sakane F,Imai S,Kai M,Yasuda S,Kanoh H

    更新日期:2008-08-01 00:00:00

  • There is a link between erectile dysfunction and heart failure: it could be inflammation.

    abstract::The rates of erectile dysfunction (ED) in heart failure (HF) are extremely high. Limited capacity of patients with HF to exercise and coronary artery disease are considered to be the main causative mechanisms. Both HF and ED are associated with increased levels of proinflammatory cytokines, such as tumor necrosis fact...

    journal_title:Current drug targets

    pub_type: 杂志文章,评审

    doi:10.2174/1389450116666150420145757

    authors: Rodrigues FL,Fais RS,Tostes RC,Carneiro FS

    更新日期:2015-01-01 00:00:00

  • ACE2/Angiotensin-(1-7)/Mas Receptor Axis in Human Cancer: Potential Role for Pediatric Tumors.

    abstract:BACKGROUND:Pediatric tumors remain the highest cause of death in developed countries. Research on novel therapeutic strategies with lesser side effects is of utmost importance. In this scenario, the role of Renin-Angiotensin System (RAS) axes, the classical one formed by angiotensinconverting enzyme (ACE), Angiotensin ...

    journal_title:Current drug targets

    pub_type: 杂志文章

    doi:10.2174/1389450121666200210124217

    authors: de Paula Gonzaga ALAC,Palmeira VA,Ribeiro TFS,Costa LB,de Sá Rodrigues KE,Simões-E-Silva AC

    更新日期:2020-01-01 00:00:00

  • Is surfactant a promising additive drug in ALI/ARDS-patients?

    abstract::The rationale for surfactant replacement therapy in patients with acute respiratory distress syndrome (ARDS) is to restore the normal composition of the surfactant system, as well as to overcome ongoing inactivation of present surfactant. Indeed, surfactant replacement therapy can normalize the composition of the surf...

    journal_title:Current drug targets

    pub_type: 杂志文章,评审

    doi:10.2174/1389450043345399

    authors: Schultz MJ,Kesecioglu J

    更新日期:2004-07-01 00:00:00

  • Pharmacological treatments for neovascular age-related macular degeneration: can mixed treatment comparison meta-analysis be useful?

    abstract:OBJECTIVE:To investigated the use of mixed treatment comparison (MTC) meta-analysis models to summarize results from randomized clinical trials (RCTs) on approved pharmacological treatments for neovascular age-related macular degeneration (AMD). METHODS:The number of patients with visual loss or visual gain of 3 or mo...

    journal_title:Current drug targets

    pub_type: 杂志文章,meta分析,评审

    doi:10.2174/138945011794182665

    authors: Virgili G,Novielli N,Menchini F,Murro V,Giacomelli G

    更新日期:2011-02-01 00:00:00

  • Potential therapeutic targets for neurodegenerative diseases: lessons learned from calorie restriction.

    abstract::It is well known that calorie restriction (CR) can retard the aging process in organisms ranging from yeast to non-human primates, and delay the onset of numerous age-related diseases including neurodegenerative disorders. Translation of the knowledge gained from CR research in animal models to disease prevention stra...

    journal_title:Current drug targets

    pub_type: 杂志文章,评审

    doi:10.2174/1389450111007011281

    authors: Duan W,Ross CA

    更新日期:2010-10-01 00:00:00

  • α7 nicotinic acetylcholine receptor mediated neuroprotection in Parkinson's disease.

    abstract::Parkinson's disease (PD) is characterized by relatively selective degeneration of dopaminergic neurons in the substantia nigra and loss of dopamine in the striatum. More than 50 epidemiological studies confirmed the low incidence of PD in smokers. Examining the distribution of subtypes of nicotinic acetylcholine recep...

    journal_title:Current drug targets

    pub_type: 杂志文章,评审

    doi:10.2174/138945012800399026

    authors: Kawamata J,Suzuki S,Shimohama S

    更新日期:2012-05-01 00:00:00

  • PD-L1 Testing for Urothelial Carcinoma: Interchangeability, Reliability and Future Perspectives.

    abstract::Five programmed death-1/programmed death-ligand 1 (PD-L1) inhibitors are currently approved for the treatment of locally advanced or metastatic urothelial carcinoma of the bladder and the upper urinary tract. Following the FDA and EMA restrictions of first-line treatment with Atezolizumab and Pembrolizumab in platinum...

    journal_title:Current drug targets

    pub_type: 杂志文章

    doi:10.2174/1389450121666200510015216

    authors: Gevaert T,Cimadamore A,Montironi R,Eckstein M

    更新日期:2020-05-09 00:00:00

  • Faecal Microbiota Transplantation in Inflammatory Bowel Disease: Current Concepts and Future Challenges.

    abstract::Dysbiosis has been repeatedly observed in inflammatory bowel disease (IBD) and is now recognized as an essential factor in the gut inflammatory process. IBD is a significant burden to health-care systems, mainly due to treatment-related costs. Available treatments have several limitations: up to 30% of patients are pr...

    journal_title:Current drug targets

    pub_type: 杂志文章

    doi:10.2174/1389450121666200602125507

    authors: Zatorski H,Nakov R

    更新日期:2020-01-01 00:00:00

  • Targeting calcium and the mitochondria in prevention of pathology in the heart.

    abstract::Calcium is a key determinant of cardiac excitation, contraction and relaxation. Cardiac excitation and contraction is powered by ATP that is synthesized within mitochondria via a calcium-dependent process known as oxidative phosphorylation. During this process oxygen molecules within the mitochondria are converted to ...

    journal_title:Current drug targets

    pub_type: 杂志文章,评审

    doi:10.2174/138945011795378603

    authors: Viola HM,Hool LC

    更新日期:2011-05-01 00:00:00

  • Multidrug transporters as drug targets.

    abstract::Transport molecules can significantly affect the pharmacodynamics and pharmacokinetics of drugs. An important transport molecule, the 170 kDa P-glycoprotein (Pgp), is constitutively expressed at several organ sites in the human body. Pgp is expressed at the blood-brain barrier, in the kidneys, liver, intestines and in...

    journal_title:Current drug targets

    pub_type: 杂志文章,评审

    doi:10.2174/138945006778019264

    authors: Liang XJ,Aszalos A

    更新日期:2006-08-01 00:00:00

  • Targeting the RAS signaling pathway in malignant hematologic diseases.

    abstract::Molecularly targeting signaling pathways that are involved in the pathogenesis of hematopoietic malignancies may lead to more specific and efficacious therapies. Activation of the RAS signal transduction cascade is a common feature in the molecular pathogenesis of hematologic malignancies. A number of novel agents tar...

    journal_title:Current drug targets

    pub_type: 杂志文章,评审

    doi:10.2174/138945007779940043

    authors: Morgan MA,Ganser A,Reuter CW

    更新日期:2007-02-01 00:00:00

  • Tachykinins: role in human gastrointestinal tract physiology and pathology.

    abstract::Tachykinins (TKs) and their receptors (NK1, NK2 and NK3), which are diffusely expressed in the human gastrointestinal tract, represent an endogenous modulator system regulating enteric secretomotor functions, inflammatory and immune responses, and visceral hypersensitivity, mainly during pathological gut diseases. Pat...

    journal_title:Current drug targets

    pub_type: 杂志文章,评审

    doi:10.2174/138945006778019354

    authors: Improta G,Broccardo M

    更新日期:2006-08-01 00:00:00

  • Triterpene derivatives as inhibitors of protein involved in the inflammatory process: molecules interfering with phospholipase A2, cycloxygenase, and lipoxygenase.

    abstract::Over the past years, there was an explosion in the knowledge of the protein target and molecular mechanism associated with various disease types and in the new research of drugs of natural origin. The key idea is to evaluate bioactive natural products interacting with protein domains of different genetic origin but st...

    journal_title:Current drug targets

    pub_type: 杂志文章,评审

    doi:10.2174/138945011794815284

    authors: Braca A,Dal Piaz F,Marzocco S,Autore G,Vassallo A,De Tommasi N

    更新日期:2011-03-01 00:00:00

  • Targeting transcription: a new concept of anti-inflammatory therapy of airway diseases.

    abstract::Most pathological conditions that result in human diseases are associated with altered gene expression. With the advent of new technologies that might control gene expression and a broader knowledge of transcription factors and pathways, new strategies have emerged that offer promising first results for therapeutical ...

    journal_title:Current drug targets

    pub_type: 杂志文章,评审

    doi:10.2174/138945006777435326

    authors: Quarcoo D,Hamelmann E

    更新日期:2006-06-01 00:00:00

  • Osteoarthritis: aging of matrix and cells--going for a remedy.

    abstract::It has been known for a very long time that aging is the most prominent risk factor for the initiation and progression of osteoarthritis. This might be related to continuous mechanical wear and tear and/or result from time/age-related modifications of cartilage matrix components. Also a mere loss of viable cells over ...

    journal_title:Current drug targets

    pub_type: 杂志文章,评审

    doi:10.2174/138945007779940070

    authors: Aigner T,Haag J,Martin J,Buckwalter J

    更新日期:2007-02-01 00:00:00

  • Unique structural motif supports mannosylphospho dolichol synthase: an important angiogenesis regulator.

    abstract::Mannosylphospho dolichol synthase (DPMS) catalyzes the transfer reaction GDP-mannose + Dol-P <--> Dol-P-Man + GDP, a 'key step' in the assembly of lipid-linked oligosaccharide (LLO) and a pre-requisite for asparagine-linked (N-linked) protein glycosylation. DPMS is present from a protozoan parasite to human, and its s...

    journal_title:Current drug targets

    pub_type: 杂志文章

    doi:10.2174/138945008783954916

    authors: Baksi K,Tavárez-Pagán JJ,Martínez JA,Banerjee DK

    更新日期:2008-04-01 00:00:00

  • Adipose tissue as a regulator of energy balance.

    abstract::Adipose tissue plays an active role in energy balance because it is not only a lipid storing and mobilizing tissue but consists of functionally specialized tissues able to produce heat (in brown adipose tissue) and to produce or release a vast number of so called adipokines or adipocytokines. These consist of polypept...

    journal_title:Current drug targets

    pub_type: 杂志文章,评审

    doi:10.2174/1389450043490523

    authors: Klaus S

    更新日期:2004-04-01 00:00:00

  • Metabolic syndrome as a modifier of atherosclerosis in murine models.

    abstract::The Metabolic Syndrome is a common metabolic disease associated with an increased risk for atherosclerotic cardiovascular disease and mortality. In contrast to "traditional" risk factors for atherosclerosis, such as low-density lipoprotein cholesterol, the Metabolic Syndrome represents a network of interacting risk fa...

    journal_title:Current drug targets

    pub_type: 杂志文章,评审

    doi:10.2174/138945007782403838

    authors: Péterfy M,Davis RC,Lusis AJ

    更新日期:2007-11-01 00:00:00

  • Non-Small Cell Lung Carcinoma: An Overview on Targeted Therapy.

    abstract::Non-small cell lung cancer (NSCLC) represents close to 90% of all lung cancers. When diagnosed, most cases are on an advanced and inoperable stage, with limited therapeutic options. Existing therapies have shown to be insufficient and novel strategies are urgently necessary. New advances in understanding the disease a...

    journal_title:Current drug targets

    pub_type: 杂志文章,评审

    doi:10.2174/1389450115666140528151649

    authors: Nascimento AV,Bousbaa H,Ferreira D,Sarmento B

    更新日期:2015-01-01 00:00:00

  • Nutrition in adult patients with inflammatory bowel disease.

    abstract::Seventy five percent of hospitalized patients with Crohn's disease suffer from malnutrition. One third of Crohn's disease patients have a body mass index below 20. Sixty percent of Crohn's disease patients have sarcopenia. However some inflammatory bowel disease (IBD) patients are obese or suffer from sarcopenic-obesi...

    journal_title:Current drug targets

    pub_type: 杂志文章

    doi:10.2174/1389450115666140930150047

    authors: Hebuterne X,Filippi J,Schneider SM

    更新日期:2014-01-01 00:00:00